|
REGULATORY
MATTERS
|
| • |
Aprotinin
|
| • |
Asenapine
maleate |
| • |
Ceftriaxone |
| • |
Citalopram
hydrobromide |
| • |
Clopidogrel
and proton-pump inhibitors |
| • |
Dasatinib |
| • |
Dronedarone |
| • |
Finasteride |
| • |
Fluconazole |
| • |
Fusidic
acid and Statins |
| • |
Gonadotropin-releasing
hormone agonists |
| • |
Isotretinoin |
| • |
Lenalidomide |
| • |
Terpenic-based
anti-cough medicines |
| • |
Tumour
Necrosis Factor-alpha Blockers |
| • |
Zoledronic
acid
|
|
SAFETY
OF MEDICINE
|
| • |
Bevacizumab
|
| • |
Bisphosphonates |
| • |
Drospirenone-containing
combined oral contraceptives |
| • |
Gadolinium
based contrast agents |
| • |
Ondansetron |
| • |
Proton
pump inhibitors |
| • |
Quinine |
| • |
Uromitexan |
| • |
Venlafaxine |
|
FEATURE
|
| • |
FIP
pharmacovigilance seminar in India
|
